Gastric Cancer: Innovations in Screening, Diagnosis and Treatment

Guest Editors:

Dr. Wenhong Deng
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China

Dr. Jun He
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China

Deadline for manuscript submissions:
closed (5 June 2023)

Message from the Guest Editors

Dear Colleagues,

Gastric cancer remains a particularly lethal disease, having the fourth highest fatality rate and the fifth highest incidence rate worldwide. This malignancy shows its symptoms in advanced stages. Therefore, one of the challenging issues regarding gastric cancer is the screening and diagnosis of these advanced stages, which causes a weak prognosis in patients with gastric malignancies. Research into various methods of early screening and diagnosis of gastric cancer, as well as new treatment options, is important for improving the prognosis. A better understanding of the different aspects of this disease could save millions of lives worldwide.

Given the importance of the early diagnosis and treatment of gastric malignancies, this Special Issue aims to bring together research that helps us to understand the innovations in screening, diagnosis, and treatment of gastric cancer. This has an important role in the development of gastric cancer. Original research articles and reviews are welcome. Research areas may include (but are not limited to) all the aforementioned topics.

Dr. Wenhong Deng
Dr. Jun He
Guest Editors

mdpi.com/si/150505

Special Issue

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.
High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.
Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us